Duncan Hines parent Conagra Brands says it will phase out artificial colors
In a statement released Wednesday – the same day as a similar statement from Nestle – Chicago-based Conagra said it will remove artificial colors from its frozen foods by the end of this year. Conagra's frozen brands include Marie Callender's, Healthy Choice and Birds Eye.
Conagra said it won't offer products containing artificial colors to K-12 schools by the beginning of the 2026-2027 school year, and it will work to discontinue artificial dyes across its entire portfolio by the end of 2027.
Kraft Heinz and General Mills made similar pledges earlier this month.
The federal government has stepped up its scrutiny of artificial colors in recent months. In January, days before President Donald Trump took office, the U.S. regulators banned the dye called Red 3 from the nation's food supply, nearly 35 years after it was barred from cosmetics because of potential cancer risk.
In April, Trump's Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said the agency would take steps to eliminate synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry.
Many of Conagra's products already make a point of using natural dyes. On a jar of Vlasic kosher pickle spears, Conagra notes that they're colored with turmeric, not the synthetic Yellow 5. For the cheesy color in its frozen vegetable sides or its Orville Redenbacher popcorn, Conagra uses annatto, a plant extract.
But some of Conagra's products still rely on synthetic colors. Duncan Hines' Comstock County Cherry pie filling uses Red 40, for example, while its Creamy Strawberries n' Cream Frosting uses both Red 40 and Yellow 5. Conagra's Swiss Miss Butterscotch pudding contains Yellow 6, Red 40 and Blue 1.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
13 minutes ago
- The Hill
2.8M in US now identify as transgender: Research
Roughly 2.8 million Americans aged 13 and older identify as transgender, accounting for approximately 1 percent of the U.S. population in that age group, according to a new estimate from the Williams Institute, a research organization focused on sexual orientation and gender identity issues. About three-quarters of people who identify as transgender in the U.S. are under 35, according to the report published Wednesday, and 25 percent are between 13 and 17. Williams Institute researchers used data from the Behavioral Risk Factor Surveillance System (BRFSS) and Youth Risk Behavior Surveillance System (YRBSS) — public health surveys administered by the Centers for Disease Control and Prevention (CDC) — and statistical modeling to estimate the population of trans adults and youth in all 50 states and Washington, D.C. About 2.1 million adults identify as transgender, accounting for approximately 0.8 percent of Americans aged 18 and older, according to Wednesday's report. Roughly 3.3 percent of 13 to 17-year-olds in the U.S., or 724,000, identify as transgender. 'Younger generations are more likely to identify as transgender, and we expect that trend to continue,' said Jody Herman, the report's lead author and a senior scholar at the Williams Institute. 'Youth and young adults are more likely to identify as transgender due to a variety of factors, including a greater willingness among younger individuals to disclose that they identify as transgender on surveys.' That finding is consistent with national surveys on LGBTQ identification. In a February Gallup poll, 23.1 percent of Gen Z said they identify as lesbian, gay, bisexual, transgender or 'something other than heterosexual,' compared with 14.2 percent of Millennials and 5.1 percent of Gen X. The Williams Institute, affiliated with the University of California, Los Angeles School of Law, has tracked the number of transgender people in the U.S. since at least 2011. In 2022, the group estimated that 1.6 million Americans identified as transgender. Most transgender people in the U.S. — about 279,000 — live in the South, according to Wednesday's report, consistent with previous years' findings. Around 175,000 transgender Americans live in the West; 156,000 in the Midwest and 114,000 in the Northeast, the Williams Institute found. Of all adults who identify as transgender, 33 percent are transgender women; 34 percent are transgender men and 33 percent are nonbinary, according to Wednesday's report. The group's estimate comes as President Trump's administration works to remove public health datasets and information from federal government websites about transgender people and identities. Affixed at the top of the CDC's webpage for the YRBSS, which the Williams Institute used in its calculation on Wednesday, is an advisory that 'Any information on this page promoting gender ideology is extremely inaccurate and disconnected from the immutable biological reality that there are two sexes, male and female.' 'The Trump Administration rejects gender ideology and condemns the harms it causes to children, by promoting their chemical and surgical mutilation, and to women, by depriving them of their dignity, safety, well-being, and opportunities,' the advisory reads. 'This page does not reflect biological reality and therefore the Administration and this Department rejects it.' Federal health agencies, including the CDC, were ordered to restore online datasets taken down after Trump issued an executive order in January prohibiting the government from promoting 'gender ideology.' Each of the restored webpages leads with notices condemning 'gender ideology.' The White House has also sought to remove questions about gender identity from national surveys on crime victimization and sexual violence. In February, former U.S. Census Bureau Director Robert Santos told NPR that the bureau had moved to strike gender identity questions from several surveys it conducts because of Trump's Jan. 20 order. 'Federal datasets that include questions about sexual orientation and gender identity have provided critical information to researchers, clinicians, policymakers, and the public,' Andrew R. Flores, a distinguished visiting scholar at the Williams Institute and one of the authors of Wednesday's report, said in a statement. 'Removal of these questions from federal surveys — such as the BRFSS and the YRBS — would significantly hinder the ability of researchers to assess the health, experiences, and needs of transgender people in the United States.'
Yahoo
27 minutes ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
Yahoo
an hour ago
- Yahoo
New malaria drug for newborn babies offers hope to parents, health workers in Uganda
Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early'. Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (about two to five kilograms). Swissmedic said the treatment, a sweet-tasting tablet that dissolves into a syrup when dropped into liquids like breast milk, was approved in coordination with the World Health Organization (WHO) under a fast-track authorisation process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95 per cent of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. Related Malaria cases surged to 263 million last year amid stalled progress to stop mosquito-borne illness In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than five and pregnant women, the WHO said. Nigeria, Congo, and Uganda – in that order – are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. How the medicine could change malaria treatment The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitising the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. Related Scientists discover drug that could make human blood deadly to mosquitos in fight against malaria During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centres across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria'. In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Related West Nile virus, chikungunya, dengue: Tracking mosquito-borne illnesses across Europe Jane Nabakooza, a pediatrician with Uganda's malaria control programme, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the United States shrank its foreign aid programme earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programmes such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under five years,' Nabakooza said.
